Literature DB >> 6336645

Glucagon enhancement of cholangiography. A preliminary report.

C A Tabak, P L Tuxen, D L Bruce, G L Juler.   

Abstract

Fourteen patients having cholecystectomies under general anesthesia were divided into two groups in a double-blind study. All had intraoperative cholangiograms, before which half had glucagon hydrochloride given intravenously in a dose of 1 mg; the others received only normal saline solution. There was a consistently superior visualization of the biliary tree in those given glucagon, and the difference was statistically significant. No significant changes in blood glucose level, heart rate, or ECG patterns were noted in either group. One patient with preoperative hypertension had a brief rise in BP after the glucagon was given. This study confirms previous anecdotal reports suggesting that glucagon in low dose enhances the quality of cholangiography without producing side effects.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6336645     DOI: 10.1001/archsurg.1983.01390010060014

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  4 in total

1.  British Association of Clinical Anatomists: Abstracts of papers presented at the Summer Meeting, July 1984.

Authors: 
Journal:  Ann R Coll Surg Engl       Date:  1985-05       Impact factor: 1.891

2.  SAGES clinical spotlight review: intraoperative cholangiography.

Authors:  William W Hope; Robert Fanelli; Danielle S Walsh; Vimal K Narula; Ray Price; Dimitrios Stefanidis; William S Richardson
Journal:  Surg Endosc       Date:  2017-03-31       Impact factor: 4.584

3.  Consequences of routine peroperative cholangiography during cholecystectomy for gallstone disease: a prospective, randomized study.

Authors:  M Hauer-Jensen; R Kåresen; K Nygaard; K Solheim; E Amlie; O Havig; K O Viddal
Journal:  World J Surg       Date:  1986-12       Impact factor: 3.352

4.  Operative cholangiography--techniques and inadequacies.

Authors:  M E Foster; D R Foster
Journal:  J R Soc Med       Date:  1984-08       Impact factor: 5.344

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.